» Articles » PMID: 35528189

Patterns of Use and Self-reported Effectiveness of Cannabis for Hyperemesis Gravidarum

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

There is limited research on effective treatment of Hyperemesis Gravidarum (HG), the most extreme version of nausea and vomiting during pregnancy (NVP). This paper examines current patterns of use and self-reported effectiveness of cannabis/cannabis-based products (CBP) to treat HG. The study employed a 21-question survey to gather information on demographics, antiemetic prescription use, and experience with cannabis/CBPs among individuals who experienced extreme nausea and vomiting or HG during their pregnancy. Age-adjusted unconditional logistic regression was used to compare odds of symptom relief and weight gain between respondents who used prescription antiemetics and those who used cannabis. Of the 550 survey respondents, 84% experienced weight loss during pregnancy; 96% reported using prescription antiemetics and 14% reported cannabis use for HG. Most respondents reported using cannabis/CBPs (71%) because their prescribed antiemetics were self-reported to be ineffective. More than half of cannabis/CBP users reported using products daily or multiple times per day (53%), primarily via smoke inhalation (59%), and mainly either delta-9-tetrahydrocannabinol (THC) only or THC dominant preparations (57%). Eighty-two percent of cannabis/CBP users reported symptom relief, compared to 60% of prescription antiemetic users. Among patients who reported weight loss during pregnancy, 56% of cannabis users reported gaining weight within two weeks of treatment, compared to 25% of prescription antiemetic users. Respondents reported using cannabis primarily because prescribed medications were self-reported to be ineffective. Although the survey approach has inherent limitations so results should be interpreted with caution, in this sample, cannabis was self-reported to be more effective than prescription medications in alleviating HG symptoms and enabling pregnancy weight gain. Therefore, depending on the safety profiles, randomized, double-blinded, placebo-controlled trials of cannabis compared to other antiemetics are warranted to determine whether cannabinoids may provide an effective alternative treatment for HG.

Citing Articles

Multi-ancestry GWAS of severe pregnancy nausea and vomiting identifies risk loci associated with appetite, insulin signaling, and brain plasticity.

Fejzo M, Wang X, Zollner J, Pujol Gualdo N, Pujol-Gualdo N, Laisk T Res Sq. 2025; .

PMID: 39764105 PMC: 11702859. DOI: 10.21203/rs.3.rs-5487737/v1.


Use of cannabis to manage symptoms of mental and physical health conditions during pregnancy: analysis of a pro-cannabis pregnancy forum.

Gunn R, Aston E, Artis L, Nesi J, Pedersen E, Micalizzi L Front Psychiatry. 2024; 15:1478505.

PMID: 39720438 PMC: 11667102. DOI: 10.3389/fpsyt.2024.1478505.


Risk Factors for Infusions, Emergency Room Visits and Hospitalizations for Hyperemesis Gravidarum: New Data and Literature Review.

de Vera S, Brecht-Doscher A, Fejzo M, Brecht M, Kwon I, MacGibbon K Int J Womens Health. 2024; 16:1789-1802.

PMID: 39493662 PMC: 11531718. DOI: 10.2147/IJWH.S371458.


"I don't need my kid to be high": prioritizing harm reduction when using cannabis during pregnancy.

Gould E, Ganesh S, Ceasar R Harm Reduct J. 2024; 21(1):166.

PMID: 39252036 PMC: 11382473. DOI: 10.1186/s12954-024-01046-2.


Third generation antiseizure medications exposure during pregnancy and neonatal adverse birth outcomes: A systematic review.

Goubran J, Okunnu O, Lavu A, Eltonsy S Sci Prog. 2024; 107(2):368504241234781.

PMID: 39053015 PMC: 11282516. DOI: 10.1177/00368504241234781.


References
1.
Fejzo M, Arzy D, Tian R, MacGibbon K, Mullin P . Evidence GDF15 Plays a Role in Familial and Recurrent Hyperemesis Gravidarum. Geburtshilfe Frauenheilkd. 2018; 78(9):866-870. PMC: 6138473. DOI: 10.1055/a-0661-0287. View

2.
Fejzo M, Trovik J, Grooten I, Sridharan K, Roseboom T, Vikanes A . Nausea and vomiting of pregnancy and hyperemesis gravidarum. Nat Rev Dis Primers. 2019; 5(1):62. DOI: 10.1038/s41572-019-0110-3. View

3.
Einarson T, Piwko C, Koren G . Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis. J Popul Ther Clin Pharmacol. 2013; 20(2):e171-83. View

4.
Meinich T, Trovik J . Early maternal weight gain as a risk factor for SGA in pregnancies with hyperemesis gravidarum: a 15-year hospital cohort study. BMC Pregnancy Childbirth. 2020; 20(1):255. PMC: 7189646. DOI: 10.1186/s12884-020-02947-3. View

5.
Fejzo M, Fasching P, Schneider M, Schwitulla J, Beckmann M, Schwenke E . Analysis of GDF15 and IGFBP7 in Hyperemesis Gravidarum Support Causality. Geburtshilfe Frauenheilkd. 2019; 79(4):382-388. PMC: 6461465. DOI: 10.1055/a-0830-1346. View